Haemonetics Corp (HAE) valuation
Haemonetics P/E ratio history
Haemonetics trades at 57.8 times its earnings over the last twelve months and 22.1 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 19.1 (year to Mar 2025) to 85.1 (year to Mar 2018), with a median of 68.7.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Mar 28, 2026 | $54.04 | $2.05 | 26.4 | 10.3 |
| Mar 29, 2025 | $63.19 | $3.31 | 19.1 | 13.0 |
| Mar 30, 2024 | $85.35 | $2.29 | 37.3 | 19.9 |
| Apr 1, 2023 | $82.75 | $2.24 | 36.9 | — |
| Apr 2, 2022 | $63.85 | $0.84 | 76.0 | 23.0 |
| Apr 3, 2021 | $112.04 | $1.55 | 72.3 | — |
| Mar 28, 2020 | $100.95 | $1.47 | 68.7 | — |
| Mar 30, 2019 | $87.48 | $1.05 | 83.3 | — |
| Mar 31, 2018 | $73.16 | $0.86 | 85.1 | — |
| Apr 1, 2017 | $40.57 | -$0.50 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Haemonetics valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| HaemoneticsHAE | $5.44B | 57.8 | 22.1 | 4.0 |
| Waystar HoldingWAY | $5.37B | 40.0 | 15.8 | 4.5 |
| Cogent BiosciencesCOGT | $5.30B | — | — | — |
| Scholar Rock HoldingSRRK | $5.26B | — | — | — |
| Lifestance Health GroupLFST | $5.20B | 103.3 | 33.9 | 3.3 |
| Cg OncologyCGON | $5.71B | — | — | 916.0 |
| Mirum PharmaceuticalsMIRM | $5.18B | — | — | 8.4 |
| Concentra Group Holdings Parent InCON | $5.17B | 26.1 | 23.1 | 2.3 |
| Merit Medical SystemsMMSI | $5.15B | 32.3 | 18.9 | 3.2 |
| Peer median | 36.2 | 21.0 | 3.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: HAE financials · HAE returns
No forecast, no recommendation. This page describes Haemonetics Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.